Repression of interferon regulatory factor-4 (IRF4) hyperactivation restricts murine lupus

作者：Shijun He, Huihua Ding, Li Chen, Yiwei Shen, Yuting Liu, Fenghua Zhu, Xiaoqian Yang, Nan Shen, Zemin Lin, Jianping Zuo · 发表于：Signal Transduction and Targeted Therapy · 年份：2023 · DOI：10.1038/s41392-023-01413-8 · 被引用次数：16 · 研究领域：Systemic Lupus Erythematosus Research、Cytokine Signaling Pathways and Interactions、interferon and immune responses

Hyperactivation of the type I interferon (IFN) signature has been observed in several systemic autoimmune conditions, and the type I IFN receptor antagonist Saphnelo (anifrolumab-fnia) has been approved in 2021 by the Food and Drug Administration (FDA) in the US. The launch of Saphnelo marked the only new treatment approved for systemic lupus erythematosus (SLE) in more than 10 years.